ENTRY       D03605                      Drug
NAME        Crofelemer (USAN);
            Fulyzaq (TN);
            Mytesi (TN)
PRODUCT     MYTESI (Napo Pharmaceuticals)
REMARK      ATC code: A07XA06
            Product: D03605<US>
EFFICACY    Antidiarrheal
COMMENT     For the symptomatic relief of non-infectious diarrhea in adult patients with HIV/AIDS on anti-retroviral therapy
TARGET      CFTR (ABCC7) [HSA:1080] [KO:K05031]
            CLCA [HSA:1179 9635 22802] [KO:K05027 K05028 K05030]
  PATHWAY   hsa04924(1179+22802+9635)  Renin secretion
            hsa04971(1080)  Gastric acid secretion
            hsa04972(1080+1179+22802+9635)  Pancreatic secretion
BRITE       Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
             A ALIMENTARY TRACT AND METABOLISM
              A07 ANTIDIARRHEALS, INTESTINAL ANTIINFLAMMATORY/ANTIINFECTIVE AGENTS
               A07X OTHER ANTIDIARRHEALS
                A07XA Other antidiarrheals
                 A07XA06 Crofelemer
                  D03605  Crofelemer (USAN) &lt;US&gt;
            USP drug classification [BR:br08302]
             Gastrointestinal Agents
              Anti-Diarrheal Agents
               Crofelemer
                D03605  Crofelemer (USAN)
            Target-based classification of drugs [BR:br08310]
             Ion channels
              Other ion channels
               Chloride channel
                CLCA
                 D03605  Crofelemer (USAN) &lt;US&gt;
             Transporters
              ABC transporters
               ABCC subfamily
                CFTR (ABCC7)
                 D03605  Crofelemer (USAN) &lt;US&gt;
            New drug approvals in the USA [br08319.html]
             New molecular entities and new therapeutic biological products
              D03605
            New drug approvals in the USA, Europe and Japan [br08328.html]
             Approval dates by FDA, EMA and PMDA
              D03605
DBLINKS     CAS: 148465-45-6
            PubChem: 17397714
///
